Chairman: Dr. Itamar Borowitz
Phoenix Insurance Company, Mapi Pharma, Generali Financial Holdings
Prof. Arkin was appointed Vice president and Head of the Authority for Research and Development at the Hebrew University of Jerusalem in 2009. He conducted his bachelor's degree at the Robert H. Smith Faculty of Agriculture, Food and Environment at the Hebrew University and at the Faculty of Life Sciences at Tel Aviv University, and completed his doctorate in cell biology at Yale University. From 1997-2000, he was a lecturer in the department biochemistry at Cambridge University, after which he joined the faculty of the Hebrew University as an associate Professor, where he was awarded the Alon Fellowship. In 2001, he was promoted to full professor in 2005. He was appointed chair of the Alexander Silberman Institute of Life Sciences in 2008. Prof. Arkin's research deals with computational (bioinformatics) and experimental structural biology of membrane proteins, and use and development of novel experimental and computational approaches to elucidate membrane proteins structure.
Dr. Blumenfeld has recently retired from GE Medical Systems, having been with GE for over 34 years, the last 3 1/2 years as Managing Director of GE Medical Systems in Israel. He joined Medical Systems from GE’s Research Center in 1975 to initiate GE’s CT business, and up to 1981 served as the Manager of CT Market Development and then as the Manager of CT Applications. In 1983 he became Product General Manager, for GE's MR business, and during the period 1990-1998 led a “startup” within GE. Dr. Blumenfeld currently serves as the Managing Director of Meditech Advisors company, and as a member of the Board of Yissum Research Development Company, the technology transfer company of the Hebrew University.
Gideon is one of the managers of Eurofund, an Israeli based Venture Capital fund. He joined Eurofund in 2002 after completing his Bachelor of Science in Communications Technologies, Summa cum laude, from New York University. He is a board member of Dan Hotels Corp., Israel's leading Hotel chain and Freiberger Compound Materials GmbH, one of the world's leading manufacturers of compound semiconductor substrates for the microelectronics and optoelectronics industries.
Mr. Geller co-founded Medica in 1995. He is a veteran of the US and Israeli healthcare industries.
for over 30 years.
Previously he held the positions of CEO of Ikapharm, CEO of Interpharm and EVP of Teva Pharmaceuticals Group. Mr. Geller is former head of the Israeli Pharmaceutical Manufacturers Association and Tel Aviv Stock Exchange board member
Mr. Amos Mar-Haim has been a member of the Governing Council of the Van Leer Group Foundation since 1995, following a varied career in government and industry. After graduating from the Hebrew University in Jerusalem, he spent over a decade with the Israeli Ministry of Trade and Industry, rising to the position of Director General. His business career began in 1979 as Director General of AML Corp. Ltd., then of Clal Industries Ltd. He was Deputy Chairman of the Board of the Israel Corporation Ltd., one of the leading investment groups in Israel. Mr. Mar-Haim was Chairman of the Board of Zim Israel Navigation Company Ltd., Deputy Chairman of the Board of Israel Chemicals Ltd., member of the boards o the Dead Sea Works, Bromine Company Ltd., Rotem Ampert Negev and many other industrial companies. From 1989 to 1994 Mr. Mar-Haim served as Senior Deputy Mayor of Jerusalem and later as the Mayor of the city of Bnei-Brak. He also was the Chairman of the Israel Postal Authority and member of the Advisory Board of the Bank of Israel. Currently he is the Chairman of the Board of Atara Investment Co. Ltd. and Chairman of the Board of Merkazit Underwriting and Investment Banking Ltd. He is a member of the Boards of Merican Israeli Paper Mills Ltd., Roqozin Industries Ltd., Keter (Publishing) Ltd., Mehadrin Ltd. and other companies. He is the Chairman of the Association of the Stock Exchange Listed Corporations.
Mr. Roy Navon is a Managing Director of J.P. Morgan. He has 16 years of Wall Street experience and currently serves as J.P. Morgan’s Senior Country Officer for Israel and Central Asia. Prior to this role, Mr. Navon was a senior member of JPMorgan’s Financial Institutions Group in New York and served on the firm's Capital Allocation Task Force.
Prior to joining JPMorgan in 2002, Mr. Navon was a Vice President of Goldman, Sachs & Co.’s Merchant Banking Division where he led investments in technology companies serving on several boards of directors. He also spent several years in Goldman Sachs’ Financial Institutions Group.
Mr. Navon holds graduate degrees in law and economics from Stanford University and a bachelor degree from the Hebrew University of Jerusalem.
Dr. Hadar Ron, is a Managing Director at IHCV - Israel Healthcare Ventures (IHCV) is a venture capital fund dedicated to providing venture capital investment to Israeli life sciences companies. Dr. Ron has an extensive medical, legal and management experience gained in senior positions in a range of insurances companies, law firms, medical and educational institutions. Her legal and management expertise includes venture capital consulting, medical malpractice, general and medical insurance, and legal practice. In the medical field, Dr. Ron has spearheaded several research initiatives and has developed and taught courses on medical law. Dr. Ron holds MD and LLB degrees from Tel Aviv University and has studied in advanced courses at Boston University School of Medicine and at the School of Business Administration at Tel Aviv University.
Osnat Ronen was appointed to the Board of Directors of Partner in December 2009 and has served as a General Partner of Viola Private Equity since January 2008. From 2001 until 2007, Ms. Ronen was the Deputy Chief Executive Officer of Leumi Partners Ltd. the investment banking services arm of the Leumi Group where she was responsible for the Group’s Private Equity portfolio. Between 2004 and 2007, Ms. Ronen led the strategic planning, deployment and execution of the Bachar Reform, one of Israel’s largest financial reforms, at Leumi Group. As part of the implementation, Ms. Ronen managed the sale of Leumi’s holdings in mutual, provident and training funds. Prior to these positions, she served as Deputy Head of the Subsidiaries Division of The Leumi Group from 1999 until 2001. Mrs. Ronen served on the Boards of Directors of the following companies: the Paz Group, Direct-I.D.I. Insurance Company Ltd., Leumi Card Ltd., Arab Israeli Bank, Leumi Mortgage Bank and more. Currently Mrs. Ronen serves as a director on the Board of Directors of the following companies: Orad Hi-tech Ltd., Amiad Filtration Systems Ltd., Aeronautics Ltd., Degania Medical Ltd., Matomy Media Group Ltd. and Fox-Wizel Ltd. Mrs. Ronen holds an M.B.A. degree and a BSc degree in mathematics and computer science from Tel Aviv University.
Ms. Billy Shapira is the Hebrew University’s Director General. Previously Ms. Shapira served in various roles at the university, and since 2002 she was the Director of the Student’s Administration Division. She holds a M.A in Public Policy (Cume Laude), and B.A in Russian studies and International Relation (Cum Laude).
Hermona Soreq, professor of molecular biology and the elected Dean at the Faculty of Mathematics and Natural Science, received her PhD from the Weizmann Institute of Science in 1976. She serves on the boards of Makhteshim Agan and of the Oligonucleotide Therapeutic Society. Prof. Soreq has authored over 400 scientific publications and is the recipient of several prizes including the Teva and the Landau Prize and Hebrew University’s Kay Prize as well as honorary degrees at Stockholm, Buenos-Aires, Erlangen-Nuremberg and Beer-Sheva. She is a member in the Israeli Council for Research and Development, Health Advisory Committee of The European Community’s 7th Program, European Molecular Biology Organization (EMBO), Human Genome Organization (HUGO) and a number of professional societies and editorial boards.
Mr. Yoram Tietz is the Managing Partner of Ernst & Young Israel, a member firm of Ernst & Young Global and in addition serves as an advisor to E&Y Global Strategic Growth Markets group.
Before becoming the Managing Partner, Mr. Tietz was the head of the High Tech practice and a member of a Venture Capital Advisory Group. He has over 20 years experience in serving major clients, providing professional services to hundreds of startups and publicly traded high tech companies as well as Venture Companies and Private Equities investing in the high tech sector. He has also participated in many M&A’s and IPO’s on NASDAQ and others Public Capital Markets. Yoram is a Board member of the IATI (Israel Advanced Technology Industries).
Gadi Tirosh oversees and leads JVP's investments in the media, web, gaming and application space.
Prior to JVP, Gadi was Corporate VP of Product Marketing and member of the executive committee for NDS, a leader in digital pay-TV systems, supporting some of the largest digital broadcast platforms such as DIRECTV, BSkyB, Canal Digital and more. In recent weeks it was announced that Cisco Systems was due to acquire NDS for $5bn. At NDS, Gadi established the business of digital interactive TV in the late 90s, catering to the likes of Sky Sports, MTV, Discovery, QVC and other leading TV channels.
Prior to NDS, Gadi held a variety of positions in software and Internet-based R&D organizations, including Director of Product Marketing at ServiceSoft Corp.
Gadi holds a B.Sc. in Computer Science and Mathematics as well as an Executive MBA from the Hebrew University.